A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6
Research output: Contribution to journal › Journal article › Research › peer-review
To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.
| Original language | English |
|---|---|
| Journal | European Urology |
| Volume | 42 |
| Issue number | 3 |
| Pages (from-to) | 204-11 |
| Number of pages | 8 |
| ISSN | 0302-2838 |
| Publication status | Published - 2002 |
ID: 48470998